Repurposing of Four Drugs as Anti-SARS-CoV-2 Agents and Their Interactions with Protein Targets
Although there are existing vaccines against severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), new COVID-19 cases are increasing due to low immunization coverage and the emergence of new variants. For this reason, new drugs to treat and prevent severe COVID-19 are needed. Here, we provid...
Saved in:
Main Authors: | Luis C. Vesga (Author), Camilo A. Ruiz-Hernández (Author), Jeimmy J. Alvarez-Jacome (Author), Jonny E. Duque (Author), Bladimiro Rincon-Orozco (Author), Stelia C. Mendez-Sanchez (Author) |
---|---|
Format: | Book |
Published: |
MDPI AG,
2022-04-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Seroprevalencia de SARS-CoV-2 y factores asociados en migrantes con vocación de permanencia, Bucaramanga, Colombia
by: Ruth Aralí Martínez Vega, et al.
Published: (2022) -
Repurposing carrimycin as an antiviral agent against human coronaviruses, including the currently pandemic SARS-CoV-2
by: Haiyan Yan, et al.
Published: (2021) -
SARS-CoV-2: Virology and Drug Repurposing Approaches
by: Ratika Rahmasari, et al.
Published: (2020) -
Rapamycin: Drug Repurposing in SARS-CoV-2 Infection
by: Jiri Patocka, et al.
Published: (2021) -
Drug Repurposing Screen for Compounds Inhibiting the Cytopathic Effect of SARS-CoV-2
by: Catherine Z. Chen, et al.
Published: (2021)